Alzamend Neuro, Inc.

With 62 biopharmaceutical company initial public offerings in the US during the first half of 2021, this year is on track to beat 2020’s record-setting total of 86 drug developer IPOs. If drug develop

Initial public offerings by biopharmaceutical companies are back on an above-average track after eight firms went public in the US during the week of 14 to 18 June, raising $1.46bn combined, including

[Johnson & Johnson Innovation - JLABS] has been launching its JLABS sites within biotechnology hubs such as Boston, San Diego and San Francisco since 2012, but it chose Philadelphia as the site for it